KR101275660B1 - 베타-알라닌의 지속적 방출을 위한 조성물 및 방법 - Google Patents

베타-알라닌의 지속적 방출을 위한 조성물 및 방법 Download PDF

Info

Publication number
KR101275660B1
KR101275660B1 KR1020127017805A KR20127017805A KR101275660B1 KR 101275660 B1 KR101275660 B1 KR 101275660B1 KR 1020127017805 A KR1020127017805 A KR 1020127017805A KR 20127017805 A KR20127017805 A KR 20127017805A KR 101275660 B1 KR101275660 B1 KR 101275660B1
Authority
KR
South Korea
Prior art keywords
alanine
beta
free beta
free
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020127017805A
Other languages
English (en)
Korean (ko)
Other versions
KR20120094109A (ko
Inventor
로저 해리스
존 와이즈
Original Assignee
내츄럴 얼터너티브즈 인터내셔날, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 내츄럴 얼터너티브즈 인터내셔날, 인크. filed Critical 내츄럴 얼터너티브즈 인터내셔날, 인크.
Publication of KR20120094109A publication Critical patent/KR20120094109A/ko
Application granted granted Critical
Publication of KR101275660B1 publication Critical patent/KR101275660B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020127017805A 2005-05-23 2006-05-23 베타-알라닌의 지속적 방출을 위한 조성물 및 방법 Expired - Lifetime KR101275660B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68398505P 2005-05-23 2005-05-23
US60/683,985 2005-05-23
PCT/US2006/020104 WO2007073398A2 (en) 2005-05-23 2006-05-23 Compositions and methods for the sustained release of beta-alanine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077030038A Division KR101190791B1 (ko) 2005-05-23 2006-05-23 베타-알라닌의 지속적 방출을 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20120094109A KR20120094109A (ko) 2012-08-23
KR101275660B1 true KR101275660B1 (ko) 2013-06-17

Family

ID=38189110

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127017805A Expired - Lifetime KR101275660B1 (ko) 2005-05-23 2006-05-23 베타-알라닌의 지속적 방출을 위한 조성물 및 방법
KR1020077030038A Expired - Fee Related KR101190791B1 (ko) 2005-05-23 2006-05-23 베타-알라닌의 지속적 방출을 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077030038A Expired - Fee Related KR101190791B1 (ko) 2005-05-23 2006-05-23 베타-알라닌의 지속적 방출을 위한 조성물 및 방법

Country Status (8)

Country Link
US (8) US8329207B2 (cg-RX-API-DMAC7.html)
EP (2) EP3081215B9 (cg-RX-API-DMAC7.html)
JP (2) JP5336180B2 (cg-RX-API-DMAC7.html)
KR (2) KR101275660B1 (cg-RX-API-DMAC7.html)
CN (2) CN106038473A (cg-RX-API-DMAC7.html)
CA (1) CA2621365C (cg-RX-API-DMAC7.html)
DK (2) DK3081215T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007073398A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504376B2 (en) * 1996-08-12 2009-03-17 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
US5965596A (en) 1997-08-12 1999-10-12 Harris; Roger Methods and compositions for increasing the anaerobic working capacity in tissue
US8329207B2 (en) 2005-05-23 2012-12-11 Natural Alternatives International, Inc. Compositions and methods for the sustained release of beta-alanine
US7956218B2 (en) * 2007-12-12 2011-06-07 Northern Innovations And Formulations Corp. Organic salts of β-alanine
EP2231588A4 (en) * 2007-12-12 2011-02-09 Northern Innovations And Formulations Corp ORGANIC SALTS OF -ALANINE
JP5519945B2 (ja) * 2009-03-10 2014-06-11 株式会社ファンケル 抗不安剤
US20120010291A1 (en) * 2009-08-12 2012-01-12 Kneller Bruce W CREATINE Beta-ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE
US9414615B2 (en) 2010-01-18 2016-08-16 PepciCo, Inc. Gel-based compositions and methods of making same
TW201201713A (en) * 2010-04-05 2012-01-16 Abbott Lab Shelf stable nutritional liquids comprising beta alanine
WO2013056048A2 (en) * 2011-10-13 2013-04-18 Abbott Laboratories Nutritional products comprising beta-alanine
EP2800478A2 (en) * 2012-01-03 2014-11-12 Nestec S.A. Compositions and methods for the stability of reactive amino acids in a food matrix
US8496979B1 (en) * 2012-02-02 2013-07-30 Reliv International, Inc. Caffeine-free dietary supplements for increasing energy and methods of administering the same
EP2666365A1 (en) * 2012-05-22 2013-11-27 Taminco Treatment of poultry, pigs or fish for reducing the feed conversion ratio.
ITMI20121586A1 (it) * 2012-09-24 2014-03-25 N G C Medical Spa L-carnosina per il trattamento delle miopatia congenita mitocondriale e della sindrome della fatica muscolare cronica
CN103005435B (zh) * 2012-12-13 2014-01-29 北京康比特体育科技股份有限公司 一种抗疲劳、提高速度耐力的组合物及含其制剂
HUE047629T2 (hu) 2013-01-28 2020-05-28 Lopez Hector L Eljárások ß-alanin tolerancia, farmakodinamika és hatékonyság javítására és azok alkalmazása
US20150057354A1 (en) * 2013-08-20 2015-02-26 Natural Alternatives International, Inc. Method of maintaining or improving tactical performance and cognitive function through dietary supplementation
EP3261632B1 (en) * 2015-02-27 2019-07-31 Natural Alternatives International, Inc. Dietary supplementation for improving physiological responses related to post-traumatic stress disorder
US20170087108A1 (en) * 2015-09-25 2017-03-30 Natural Alternatives International, Inc. Methods of improving physiological conditions related to pregnancy through dietary supplementation
CN105663081B (zh) * 2015-12-30 2019-08-02 大连医诺生物股份有限公司 微囊化β-丙氨酸
WO2017142542A1 (en) * 2016-02-19 2017-08-24 Hewlett Packard Enterprise Development Lp Linear transformation accelerators
WO2018226987A1 (en) * 2017-06-07 2018-12-13 The Regents Of The University Of California Compositions for treating fungal and bacterial biofilms and methods of using the same
US12226386B2 (en) 2018-12-03 2025-02-18 The Regents Of The University Of California Compositions and methods for treating biofilms
WO2020262114A1 (ja) * 2019-06-28 2020-12-30 有機合成薬品工業株式会社 ミトコンドリア機能活性化剤
JP6749665B1 (ja) * 2019-07-18 2020-09-02 株式会社東洋新薬 経口組成物
US12508241B2 (en) * 2019-08-29 2025-12-30 University of Pittsburgh—of the Commonwealth System of Higher Education Peripheral nerve agonists suppress inflammation
WO2021236440A1 (en) 2020-05-20 2021-11-25 Advanced Food Concepts, Inc. Athletic performance enhancement composition using menthol
CN111956780A (zh) * 2020-08-28 2020-11-20 黑龙江现代物联网科技有限公司 一种用鹅肌肽制成降低人体尿酸的饮用水及其制备方法
CN113812635B (zh) * 2021-09-22 2023-12-19 大连医诺生物股份有限公司 微囊化β-丙氨酸、其制备方法及应用
WO2026017801A1 (de) 2024-07-17 2026-01-22 Hahn Carsten Mittel zur aufbringung auf hautpartien eines menschen zur leistungssteigerung von unter den hautpartien angeordneter muskeln des menschen bei anaerober belastung

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517868B2 (en) * 1999-12-20 2003-02-11 A. Reza Fassihi Amino acid modulated extended release dosage form
US6680294B2 (en) * 1996-08-12 2004-01-20 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966988A (en) 1971-07-28 1976-06-29 International Flavors & Fragrances Inc. Flavoring compositions and processes utilizing dithiazine compounds
USRE30370E (en) 1971-11-04 1980-08-12 International Flavors & Fragrances Inc. Flavoring foodstuffs with a thioester
DE2519656A1 (de) 1974-05-13 1975-11-27 Sandoz Ag Neue peptide und verfahren zu ihrer herstellung
US3934036A (en) 1975-01-23 1976-01-20 Kyorin Seiyaku Kabushiki Kaisha N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent
JPS54159393A (en) 1978-06-08 1979-12-17 Ajinomoto Co Inc Polyamino acid-coated activated carbon
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS6016934A (ja) 1983-07-06 1985-01-28 Kaneshiro Nagai 抗腫瘍剤
IT1176983B (it) 1984-10-16 1987-08-26 Zambon Spa Dipeptidi ad attivita' farmacologica
JPS61204120A (ja) 1985-03-07 1986-09-10 Kaneshiro Nagai 免疫調節剤
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
DE3613758A1 (de) 1986-04-23 1987-10-29 Consortium Elektrochem Ind Cysteinreiche, (gamma)-glutaminsaeure- und (beta)-alanin-einheiten aufweisende peptide, verfahren zu deren herstellung und ihre verwendung
FR2609893B1 (fr) 1987-01-26 1990-03-30 Rougereau Andre Composition a base d'acides amines et de vitamines utilisable en therapeutique cancerologique
JPS6442425A (en) 1987-08-11 1989-02-14 Nippon Univ Remedy for cachexia
WO1990006102A1 (en) 1988-09-28 1990-06-14 Peptide Technology Limited Compound and method for the retardation of collagen cross-linking
JPH0395125A (ja) 1989-05-23 1991-04-19 Otsuka Pharmaceut Co Ltd カルシウム代謝改善剤
IT1240336B (it) 1990-03-21 1993-12-07 Setra Composizioni farmaceutiche,dietetiche o veterinarie ad attivita' eumetabolica
JP2873493B2 (ja) 1990-08-09 1999-03-24 理化学研究所 血糖調節剤
JP2873497B2 (ja) 1990-09-03 1999-03-24 理化学研究所 脂質代謝調節剤
US5190775A (en) 1991-05-29 1993-03-02 Balchem Corporation Encapsulated bioactive substances
CA2117199C (en) 1991-09-09 2004-12-28 Jurgen Michaelis Method for the treatment of the complications and pathology of diabetes
JPH0624976A (ja) 1992-07-10 1994-02-01 Rikagaku Kenkyusho 輸液用組成物
GB9215746D0 (en) 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JP3213666B2 (ja) 1994-02-28 2001-10-02 治彦 末岡 クレアチン飲料の製造方法
DE69529043T2 (de) 1994-09-30 2003-05-08 L'oreal S.A., Paris Verwendung von einem Agonisten eines mit einem Chloridkanal assozierten Rezeptors zur Behandlung von Hautfalten
JP3595373B2 (ja) 1995-02-20 2004-12-02 治彦 末岡 クレアチン飲料
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
AU711536B2 (en) 1996-01-24 1999-10-14 Aliatros Medical A.S. Composition for treating cancer containing a ribose compound, beta-alanine, ascorbic acid and nicotinic acid
GB9611356D0 (en) * 1996-05-31 1996-08-07 Howard Alan N Improvements in or relating to compositions containing Creatine, and other ergogenic compounds
US6274161B1 (en) 1996-05-31 2001-08-14 The Howard Foundation Compositions containing creatine in suspension
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US7504376B2 (en) 1996-08-12 2009-03-17 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
CA2263184C (en) * 1996-08-12 2008-06-03 Mark Dunnett Methods and compositions for increasing the anaerobic working capacity in tissues
EA199901013A1 (ru) * 1997-05-16 2000-06-26 Амген Инк. Гели пролонгированного действия
US6019999A (en) * 1997-12-03 2000-02-01 Miller; David F. Process for making liposomal ion-exchange whey protein and products thereof
EP1043031A4 (en) 1997-12-26 2007-05-02 Astellas Pharma Inc MEDICAL COMPOSITIONS WITH DELAYED ACTIVE INGREDIENTS
US20010041187A1 (en) * 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
GB9924650D0 (en) * 1999-10-19 1999-12-22 Marathade Ltd Energy bar
JP4361710B2 (ja) 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド 徐放製剤
JP2002051730A (ja) 2000-08-08 2002-02-19 Nippon Meat Packers Inc スポーツ用食品
US6855727B2 (en) 2000-12-04 2005-02-15 Yaizu Suisankagaku Industry Co., Ltd. Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
WO2002056863A2 (en) 2000-12-29 2002-07-25 Bausch & Lomb Incorporated Sustained release drug delivery devices
GB2387101B (en) * 2001-03-02 2005-08-17 Howard Foundation Compositions containing creatine and creatinine
WO2003088947A1 (en) * 2002-04-22 2003-10-30 Experimental & Applied Sciences, Inc. Food supplements containing 4-hydroxyisoleucine and creatine
US6835397B2 (en) 2002-12-23 2004-12-28 Balchem Corporation Controlled release encapsulated bioactive substances
US8329207B2 (en) 2005-05-23 2012-12-11 Natural Alternatives International, Inc. Compositions and methods for the sustained release of beta-alanine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680294B2 (en) * 1996-08-12 2004-01-20 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
US6517868B2 (en) * 1999-12-20 2003-02-11 A. Reza Fassihi Amino acid modulated extended release dosage form

Also Published As

Publication number Publication date
US10828274B2 (en) 2020-11-10
KR101190791B1 (ko) 2012-10-12
EP3081215B1 (en) 2020-04-01
CN101309688B (zh) 2016-06-22
JP2013224310A (ja) 2013-10-31
WO2007073398A3 (en) 2007-09-07
CN106038473A (zh) 2016-10-26
US9636315B2 (en) 2017-05-02
US8329207B2 (en) 2012-12-11
CA2621365C (en) 2012-09-04
US9907769B2 (en) 2018-03-06
EP3081215A1 (en) 2016-10-19
JP5336180B2 (ja) 2013-11-06
US8980307B2 (en) 2015-03-17
KR20120094109A (ko) 2012-08-23
US20130142859A1 (en) 2013-06-06
CN101309688A (zh) 2008-11-19
CA2621365A1 (en) 2007-06-28
US12036196B2 (en) 2024-07-16
US20140017293A1 (en) 2014-01-16
DK1883406T3 (en) 2016-08-15
EP1883406A2 (en) 2008-02-06
US20210260005A1 (en) 2021-08-26
EP1883406B1 (en) 2016-07-06
US20090220575A1 (en) 2009-09-03
WO2007073398A2 (en) 2007-06-28
EP1883406A4 (en) 2009-11-04
US8394402B2 (en) 2013-03-12
US20180256528A1 (en) 2018-09-13
US20130030052A1 (en) 2013-01-31
US20150157587A1 (en) 2015-06-11
JP2008542282A (ja) 2008-11-27
EP3081215B9 (en) 2020-08-19
US20160354329A1 (en) 2016-12-08
US8496958B2 (en) 2013-07-30
DK3081215T3 (da) 2020-04-27
KR20080028374A (ko) 2008-03-31

Similar Documents

Publication Publication Date Title
US12036196B2 (en) Compositions and methods for the sustained release of beta-alanine
EP2201937A1 (en) Formulations comprising vitamin D or derivatives thereof
WO2006035900A1 (ja) コエンザイムｑ１０含有乳化組成物
AU2018100110A4 (en) Ubiquinone And Ubiquinol Compositions, And Methods Relating Thereto
JP2018505866A (ja) マルチサプリメント組成物
EP2070545A1 (en) Oral compositions for the prevention and treatment of inflammatory disorders of the colon
US20060292217A1 (en) Nutritional supplement and soft gelatin capsule delivery system
RS55057B1 (sr) Kompozicija za tretiranje steriliteta
US20180084813A1 (en) Co-Q10, Krill Oil and Vitamin D
KR20230136513A (ko) 비타민 c의 안정한 서방성 제형 및 이의 제조 방법
HK1125827A (en) Compositions and methods for the sustained release of beta-alanine
CN121985954A (zh) 用于减少与体重减轻相关的肌肉减少和/或抑制肌肉减少症的方法和组合物
CA2777233A1 (en) Compositions and methods for treating varicose veins

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20120709

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120808

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120924

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130520

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130611

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130612

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170621

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20170621

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180529

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20180529

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20190531

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20190531

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230525

Start annual number: 11

End annual number: 11